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Abstract
Objective: To retrospectively determine the frequency of N-Methyl-D-Aspartate
(NMDA) receptor (NMDAR) autoantibodies in patients with different forms of
dementia. Methods: Clinical characterization of 660 patients with dementia,
neurodegenerative disease without dementia, other neurological disorders and
age-matched healthy controls combined with retrospective analysis of serum or
cerebrospinal fluid (CSF) for the presence of NMDAR antibodies. Antibody
binding to receptor mutants and the effect of immunotherapy were determined
in a subgroup of patients. Results: Serum NMDAR antibodies of IgM, IgA, or
IgG subtypes were detected in 16.1% of 286 dementia patients (9.5% IgM,
4.9% IgA, and 1.7% IgG) and in 2.8% of 217 cognitively healthy controls
(1.9% IgM and 0.9% IgA). Antibodies were rarely found in CSF. The highest
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prevalence of serum antibodies was detected in patients with “unclassified
dementia” followed by progressive supranuclear palsy, corticobasal syndrome,
Parkinson’s disease-related dementia, and primary progressive aphasia. Among
the unclassified dementia group, 60% of 20 patients had NMDAR antibodies,
accompanied by higher frequency of CSF abnormalities, and subacute or fluctu-
ating disease progression. Immunotherapy in selected prospective cases resulted
in clinical stabilization, loss of antibodies, and improvement of functional imag-
ing parameters. Epitope mapping showed varied determinants in patients with
NMDAR IgA-associated cognitive decline. Interpretation: Serum IgA/IgM
NMDAR antibodies occur in a significant number of patients with dementia.
Whether these antibodies result from or contribute to the neurodegenerative
disorder remains unknown, but our findings reveal a subgroup of patients with
high antibody levels who can potentially benefit from immunotherapy.
Introduction
The prevalence of immunotherapy-responsive autoim-
mune dementias remains unclear and these conditions are
often misdiagnosed as primary neurodegenerative disor-
ders,1 suggesting that treatable etiologies are overlooked in
dementia patients. Generally, autoimmunity is suspected if
dementia starts subacutely, progresses rapidly, or fluctu-
ates, or if inflammatory cerebrospinal fluid (CSF) and sug-
gestive magnetic resonance imaging (MRI) findings are
present. However, 41% of immunotherapy-responsive
dementia patients of a large study had normal brain MRIs,
and many patients showed normal CSF and electroence-
phalography (EEG).1 Further complicating this diagnostic
dilemma, autoimmune-mediated cognitive decline can
progress slowly over many months, and therefore may be
mistaken for a primary neurodegenerative disorder such
as Alzheimer’s disease (AD) or frontotemporal dementia
(FTD).2–4 A novel paradigm of how autoimmunity and
neurodegeneration may interact was recently reported in a
disorder with progressive sleep dysfunction, pathological
findings consistent with tauopathy, and antibodies against
the neuronal cell surface protein IgLON5.5 In search of
serologic clues to autoimmune dementia, the presence of
N-Methyl-D-Aspartate receptor (NMDAR) antibodies of
the IgA isotype has recently been described in a small
cohort of patients with atypical dementia.6 Purified IgA
containing NMDAR IgA antibodies caused substantial loss
of NMDARs and further synaptic proteins in primary hip-
pocampal cultures, resulting in marked changes of
NMDAR-mediated currents. In addition, immunotherapy
resulted in clinical improvement of neuropsychiatric
symptoms in a subgroup of patients, suggesting that
NMDAR IgA is a marker of immunotherapy-responsive
dementia.6
As neurodegenerative disorders can be clinically indistin-
guishable from autoimmune dementias, we systematically
analyzed archived serum and CSF samples from patients
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with different etiologies of dementia and controls to esti-
mate the prevalence of NMDAR antibodies and potentially
identify candidates that might respond to immunotherapy.
Methods
Patients
In all, 286 well-characterized patients with clinical diagno-
ses of AD (n = 100), behavioral variant FTD (43), primary
progressive aphasia (PPA, 22), Lewy body dementia (LBD,
11), Creutzfeldt-Jakob disease (CJD, 10), Parkinson’s dis-
ease with dementia (PDD, 25), corticobasal syndrome
(CBS), progressive supranuclear palsy (PSP, 11), Hunting-
ton’s disease (HD, 14), unclassified dementia (20) and vas-
cular dementia (30), 90 patients with neurodegenerative
disease without dementia (motor neuron disease [MND,
17], Parkinson’s disease without dementia [PD, 49], multi-
ple system atrophy [MSA, 24]), 131 patients with cerebellar
ataxia (spinocerebellar ataxia [SCA, 83], idiopathic spo-
radic ataxia [ISCA, 48]), 80 patients with other neurologi-
cal disorders (such as migraine, disc prolapse, meningioma,
cerebral vasculitis, paraneoplastic cerebellar degeneration,
progressive multifocal leukoencephalopathy, or Fabry dis-
ease), 26 patients with psychiatric disease (schizophrenia,
depression, dissociative disorders; diagnosed during clinical
workup), and 47 healthy controls were recruited. Archived
specimens were collected at the dementia clinics and
departments of Neurology or Psychiatry at the Charite Uni-
versity hospital (Berlin, Germany), Massachusetts Alzhei-
mer’s Disease Research Center (Boston, USA), Harvard
NeuroDiscovery Center (Boston, USA), Phillips University
(Marburg, Germany), University Hospital Eppendorf
(Hamburg, Germany), Paracelsus Elena Klinik (Kassel,
Germany), Center for Neurology T€ubingen (T€ubingen,
Germany), Technical University Munich (Munich, Ger-
many), Saarland University (Homburg/Saar, Germany),
University Hospital Magdeburg (Magdeburg, Germany).
Retrospective analyses were approved by the Charite
University Hospital Institutional Review Board and written
informed consent for material storage was obtained from
patients or their representatives in the respective centers.
Detection of NMDAR antibodies
Testing for NMDAR antibodies was performed by recom-
binant immunofluorescence as described.6 Briefly, plas-
mids encoding the NMDA receptor (using NR1a subunit
homodimers and equimolar NR1a/NR2b heterodimers)
were transfected into HEK293 cells, grown on cover
slides, followed by acetone fixation. Slides and control-
transfected cells were incubated with “blinded” patient
samples at starting dilution of 1:10 (serum) or undiluted
(CSF). After 30 min, slides were washed with PBS-Tween
for >5 min. Bound antibodies were labeled with Fluores-
cein-conjugated goat anti-human IgG (DiaMed, Canton,
OH; dilution 1:800), IgA (1:350), or IgM (1:500) for
30 min. Coded samples were classified by two indepen-
dent blinded assessors based on immunofluorescence.
Resting-state functional MRI
Acquisition and analysis of resting-state functional MRI
(fMRI) data was performed separately for subjects using
independent component analysis (ICA) and dual regression
as described previously.7,8 Using temporal-concatenation
ICA as implemented in FSL MELODIC,9 the default mode
network (DMN) was identified. Functional connectivity
alterations of the DMN have been shown to reflect disease
severity in various neuropsychiatric diseases, including
patients with anti-NMDAR antibodies.8 The treatment
effect (i.e., comparison of pretherapy with posttherapy
DMN functional connectivity) was assessed using the dual
regression approach.7 Statistical analysis was constrained to
the individual DMN and performed using FSL’s flameo with
correction for multiple comparisons based on Gaussian ran-
dom field theory (z > 1.98, P < 0.05, cluster corrected).
PET
Positron emission tomography (PET) analysis was per-
formed as described.6 Briefly, acquisition was started
40 min after IV injection of 250 MBq [F-18]-fluorode-
oxyglucose (FDG). Transaxial images were reconstructed
and stereotactically normalized. Follow-up PET images
were coregistered to baseline prior to stereotactical nor-
malization. Each FDG-PET image was compared with
corresponding images of a group of 28 normal control
subjects on a voxel-by-voxel basis. Only effects in clusters
of at least 125 voxels (~1 mL) were considered. For direct
visualization of changes between baseline and follow-up
PETs, voxel-based subtraction was performed.10
Epitope mapping
Cultured HEK293 cells were transiently transfected as
described previously11 using the following constructs:
wild-type NR1a, NR1a with the amino terminal domain
(ATD) deleted (deletion of residues 26–382), NR1a with
amino acid 368 mutated (N368Q), or a NR1a construct
(ATD-TM4) with amino acids 401–792 deleted (deleting
the ligand-binding domain and first 3 transmembrane
domains) such that the ATD is linked directly to the
fourth transmembrane domain (TM4) as described12 (see
Fig. 3G for illustration of constructs). Eighteen to 21
hours after transfection, cells were fixed with 4% parafor-
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maldehyde (PFA) and immunostained13 with anti-NR1a
antibody (BD Biosciences 556308, San Jose, CA, USA;
1:1000 or, for experiments using the ATD-TM4 construct,
Millipore AB1548, Billerica, MA, USA; 1:200), and patient
serum was applied (subject A0 1:500, subject A6 1:100; par-
allel control experiments used samples from patients with
NMDAR encephalitis). Coverslips were washed with PBS
and secondary antibodies applied (1:500 FITC goat anti-
human IgA [Invitrogen AHI0108, Carlsbad, CA, USA];
1:1000 Alexa Fluor 488 goat anti-human IgG for control
experiments; 1:1000 Alexa Fluor 568 goat anti-mouse or
goat anti-rabbit). Cells were imaged on a Leica DMR
microscope (Leica Microsystems, Wetzlar, Germany).
Results
Detection of NMDAR antibodies in dementia
patients
Having recently identified IgA-NMDAR antibodies in
some patients with unclassified dementia (Berlin cohort),
we now aimed to compare the presence of NMDAR
autoantibodies with established forms of dementia and
neurodegenerative disorders. For this, archived serum and
CSF samples from 660 subjects were recruited from 10
dementia clinics in Germany and the United States and
retrospectively analyzed for NMDAR antibodies. Subjects
included 286 well-characterized patients with dementia, 90
patients with neurodegenerative disease without dementia,
80 controls with other neurological (non-neurodegenera-
tive) disorders, 26 patients with psychiatric disease, and 47
age-matched healthy controls (mean age 66.7 years).
IgM, IgA, or IgG NMDAR antibodies were analyzed in a
blinded fashion and detected in the serum of 16.1% of the
286 patients with different forms of dementia (9.5% IgM,
4.9% IgA, and 1.7% IgG), but only in 3.3% of 90 nonde-
mented patients with neurodegenerative disorders, 1.3% of
80 patients with other neurological diseases, and 4.3% of 47
age-matched healthy controls (Fig. 1A), representing an
average of 2.8% among controls (1.9% IgM, 0.9% IgA).
Antibodies were detected in routine assays of NMDAR-
transfected cells (Fig. 1B, left) revealing identical results in
two laboratories (L€ubeck, Barcelona). However, binding to
primary hippocampal neurons was only detectable when
high antibody titers were present (Fig. 1B, right), while
binding to rat brain sections could not be demonstrated
using short-incubation routine procedures (not shown).
Varying prevalence of NMDAR antibodies
among dementia groups
The presence of NMDAR antibodies was not uniformly
distributed among the cohorts of patients with neurode-
generative disorders (Fig. 2). Most prominently, patients
with neurodegenerative disease but without dementia
(MND, PD, MSA) had antibody frequencies in the range
of controls. Specifically, PD patients had a significantly
lower percentage compared with PDD (2% vs. 20%,
P = 0.0067, Fisher’s exact test). Serum frequency was
between 14% and 55% in patients with PPA, LBD, and
PSP/CBS, 9–12% in FTD, AD, HD, CJD, and ataxias, and
not detected in vascular dementia patients (Fig. 2A and
B). NMDAR antibodies in CSF were detected only in 11
of 334 available samples (Fig. S1). Interestingly, in all CSF
cases, low titers (≤1:10) of IgA isotype antibodies were
Figure 1. High frequency of N-Methyl-D-Aspartate receptor (NMDAR)
antibodies in dementia. Percentage of NMDAR antibody-positive
patients (serum, A) and detection of NMDAR antibodies using
transfected HEK cells and primary hippocampal neuronal cultures (B).
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present, seen in patients with unclassified dementia
(n = 4), FTD (3), vascular (1), other neurological disor-
ders (OND) (1), AD (1), and psychosis (1).
Among all dementia patients, those with progressive
cognitive dysfunction of unclear etiology from the Berlin
cohort showed the highest frequency of NMDAR antibod-
ies (60%, Fig. 2A). The term “unclassified” describes the
difficulties to assign the patients to one of the established
dementia groups. In fact, the distinct clinical characteris-
tics (see Table 1 for details) define a subgroup of
dementia patients in which there is a higher frequency of
CSF abnormalities (69%), rapid onset or fluctuating dis-
ease course (95%), immune challenges (current infection,
cancer, or concomitant autoimmune disease, 63%), and
psychiatric abnormalities (75%) (Table 1). Difficulties in
establishing a clear dementia diagnosis in several cases
also resulted from imaging abnormalities, such as
leukoencephalopathy, focal or rapidly developing atrophy,
or heterogeneously reduced glucose uptake without
underlying atrophy (Fig. 3A–D).
Association of clinical signs and NMDAR
antibodies
Irrespective of the type of dementia, the presence of
NMDAR antibodies was associated with certain clinical
features (Table 2). Compared to NMDAR antibody-nega-
tive patients, antibody-positive patients more often
Figure 2. Frequency distribution, isotypes, and titers of serum N-
Methyl-D-Aspartate receptor (NMDAR) antibodies in study subjects.
Number of subjects per group, percentage of dementia patients and
controls with positive NMDAR antibodies (IgM, IgA, or IgG) in serum
(A). Antibody isotypes and serum titers across dementia groups and
controls (B).
Table 1. Clinical characteristics of patients with “unclassified dementia” compared to other forms of dementia.
Unclassified
(“Unclassified”) AD PD FTD CBS/PSP LBD
Irregular progression1 95% (20) 13% (31) 14% (14) 27% (11) 27% (11) 17% (6)
Cognitive deficits 100% (20) 100% (31) 57% (14) 100% (11) 100% (11) 100% (6)
Aphasia 68% (19) 58% (31) 21% (14) 91% (11) 63% (11) 80% (5)
Psychiatric symptoms2 75% (20) 32% (31) 14% (14) 64% (11) 36% (11) 83% (6)
Epileptic seizures 23% (17) 13% (31) 0% (14) 0% (11) 0% (11) 0% (6)
Further CNS signs 68% (19) 32% (31) 100% (14) 45% (11) 100% (11) 100% (6)
Extrapyramidal 47% (19) 26% (31) 100% (14) 36% (11) 100% (11) 100% (6)
Cerebellar 47% (19) 3% (31) 0% (14) 0% (11) 0% (11) 0% (6)
CSF abnormalities 69% (16) 32% (28) 0% (11) 27% (11) 30% (10) 0% (6)
Pleocytosis3 12% (16) 0% (28) 0% (11) 0% (11) 10% (10) 0% (6)
BBB dysfunction 50% (16) 32% (28) 0% (11) 27% (11) 20% (10) 0% (6)
OCB3 38% (16) 4% (28) 0% (10) 0% (11) 0% (8) 0% (4)
Immune challenges4 63% (19) 32% (31) 21% (14) 36% (11) 20% (10) 17% (6)
Positive family history (dementia) 17% (18) 16% (31) 14% (14) 27% (11) 0% (10) 33% (6)
AD, Alzheimer’s disease; PD, Parkinson’s disease; FTD, frontotemporal dementia; CBS, corticobasal syndrome; PSP, progressive supranuclear palsy;
LBD, Lewy body dementia; CSF, cerebrospinal fluid; CNS, central nervous system.
1Subacute onset, partial regression, or plateau.
2Affective symptoms, irritability, aggression, delusions, hallucinations.
3OCB, oligoclonal bands in the CSF. Pleocytosis >4 white blood cells per lL CSF.
4Current infection, cancer, or other autoimmunity.
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showed subacute disease onset or fluctuating disease pro-
gression (21.1% vs. 52.8%, P = 0.003, Fisher’s exact test),
aphasia (50% vs. 77.1%, P = 0.014), and CSF abnormali-
ties, in particular blood–brain barrier dysfunction as
defined by increased CSF/serum albumin quotients
(17.0% vs. 44.1%, P = 0.012) (Table 2). In contrast, psy-
chiatric symptoms, extrapyramidal movement disorders,
or frequency of accompanying cancer were rather equally
distributed between both groups (Table 2). NMDAR anti-
bodies were usually not present in cases with a positive
family history of dementia (24.5% vs. 2.9%, P = 0.0067).
The analysis was intended as an exploratory statistical
analysis to generate hypotheses for further discussions
and planning of prospective trials, thus no adjustments
for multiple testing have been made.
Patients with high NMDAR antibody titers
can benefit from immunotherapy
Due to the retrospective nature of this study, a systematic
analysis of the effect of immunotherapies is not possible.
However, from five prospectively included patients with
unexplained dementia and highly positive NMDAR IgA
antibodies (titers ≥1:1000), two patients were selected for
an immunotherapy attempt. Both received high-dose
methylprednisolone and plasma exchange, in one case fol-
lowed by cyclophosphamide. One patient markedly
improved in the first weeks (cognitive testing, alertness,
aphasia, and motivation) and both patients did not pro-
gress during the follow-up of 8–12 months. The clinical
improvement was supported by imaging findings. Both
patients underwent resting-state fMRI before and after
plasma exchange which showed a significantly increased
DMN functional connectivity in pretreatment scans
(Fig. 3E). This is in line with correlations of increased
DMN synchronization with severity of cognitive dysfunc-
tion in neuropsychiatric diseases, including AD, multiple
sclerosis, and schizophrenia.14–16 Available in one of the
two cases, PET studies documented significant improve-
ment of cerebral metabolism in cortical brain areas after
plasma exchange (Fig. 3F).
IgA antibodies bind to different epitopes of
the NMDA receptor
HEK cells were transfected with different NR1 mutants
(Fig. 3G). Immunostaining was performed with serum of
two patients with the highest titers (Fig. 3H and I). Paral-
lel control experiments using samples from patients with
NMDAR-IgG encephalitis were also performed (data not
Figure 3. Imaging findings in dementia patients with NMDAR antibodies and epitope mapping with IgA-positive serum. Several patients with
unclassified dementia and IgA/IgM NMDAR antibodies showed MRI and PET abnormalities that were not typical of primary neurodegenerative
disorders. These included patients with otherwise unexplained marked bilateral leukoencephalopathy (A), global atrophy associated with very
rapidly developing dementia (B and C), or patchy FDG uptake with reduction in paraventricular and cortical areas (D). NMDAR antibody levels in
these patients were IgA 1:100 in serum and 1:10 in CSF (A), IgM 1:3200 in serum (B), IgA 1:1000 in serum (C and D). Imaging demonstrates
treatment effects following immunotherapy with plasma exchange using fMRI (E) and PET (F). Functional connectivity of the default mode
network (a set of brain regions with strongly correlated neural activity) was significantly decreased with the posterior cingulate cortex, the
precuneus, and the superior parietal cortex in posttreatment scans in comparison with pretreatment scans (E). PET studies in a patient with
unclassified dementia and IgA antibodies documented significant improvement of cerebral metabolism in cortical brain areas after plasma
exchange (F). HEK cells were transfected with wild-type NR1a, or with NR1a mutants lacking the amino terminal domain (ATD-deleted), with
amino acid 368 mutated (N368Q), or lacking the ligand-binding domain and first 3 transmembrane domains (ATD-TM4) (G). Subject A0 had IgA
antibodies that strongly recognized NR1a. ATD deletion and N368Q mutation both only mildly reduced antibody binding while binding to the
ATD-TM4 construct was increased (H; NR1a commercial antibody staining in red, human IgA antibodies in green; insert – corresponding grayscale
images of human IgA). Subject A6 had IgA antibodies that recognized NR1a. For this subject, ATD deletion and N368Q mutation nearly
eliminated staining of the NR1a construct and the antibodies had reduced binding to the ATD-TM4 construct (I). NMDAR, N-Methyl-D-Aspartate
receptor; FDG, [F-18]-fluorodeoxyglucose; fMRI, functional magnetic resonance imaging; CSF, cerebrospinal fluid.
Table 2. Clinical characteristics of antibody-positive versus -negative
patients (all dementia groups).
NMDAR
ab-positive
NMDAR
ab-negative P1
Irregular progression 19/36 (52.8%) 12/57 (21.1%) 0.0032
Aphasia 27/35 (77.1%) 28/56 (50.0%) 0.0142
Psychiatric symptoms3 20/36 (55.6%) 26/56 (46.4%) 0.52
Further CNS signs 24/34 (70.6%) 34/56 (60.7%) 0.37
Extrapyramidal 20/34 (58.8%) 30/56 (53.6%)
Cerebellar 5/34 (14.7%) 5/56 (8.9%)
Blood–brain barrier
dysfunction
15/34 (44.1%) 8/47 (17.0%) 0.0122
OCB/pleocytosis4 6/34 (17.6%) 5/47 (10.6%) 0.51
Cancer5 4/33 (12.1%) 6/57 (10.5%) 0.99
Positive family
history (dementia)
1/35 (2.9%) 13/53 (24.5%) 0.00672
NMDAR, N-Methyl-D-Aspartate receptor.
1Fisher’s exact test (exploratory, e.g., uncorrected for multiple com-
parisons).
2P < 0.05 is considered significant.
3Affective symptoms, irritability, aggression, delusions, hallucinations.
4OCB, oligoclonal bands in the CSF only. Pleocytosis >4 white blood
cells per lL CSF.
5Cancer within 1 year of presentation.
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shown). Subject A0, who improved markedly after immu-
notherapy, had IgA antibodies that strongly recognized
NR1a. ATD deletion and N368Q mutation both only par-
tially reduced antibody binding while binding to the
ATD-TM4 construct was increased (Fig. 3H). Subject A6,
who had a milder response to immunotherapy, had IgA
antibodies that recognized NR1a. For this subject, ATD
deletion and N368Q mutation nearly eliminated NR1a
staining and the antibodies had reduced binding to the
ATD-TM4 construct (Fig. 3I). Taken together, epitope
specificity varies between patients. The results suggest that
the ligand-binding domain and first 3 transmembrane
domains are not necessary for recognition by subject A0’s
antibodies, and that the ATD, TM4, or intracellular c-ter-
minal tail are sufficient for recognition. In subject A6, the
ATD, and amino acid 368 within the ATD, seem to be
important for antibody recognition; however, the ligand-
binding domain or TM1-3 may also contribute to epitope
formation. For neither subject were the ATD or amino
acid 368 as crucial as they are for epitope recognition of
IgG antibodies from patients with anti-NMDAR encepha-
litis (data not shown, see also12).
Discussion
Contribution of autoantibodies to neurodegeneration has
been suspected for a long time and correlations of
increased antibody titers with dementia have been shown
for very diverse autoantibodies ranging from anti-GM1,17
anti-adrenergic receptors,18 to antibodies against tau
protein, neurofilaments,19 b-amyloid,20 GFAP21, or neuro-
transmitters.22 However, selection of dementia patients
that could potentially benefit from immunotherapy is
challenging, mainly because of limited understanding of
the pathogenic role of individual antibodies and the lack
of systematic data showing clinical improvement of auto-
antibody-positive dementia patients with immunotherapy.
The finding of high-titer IgA/IgM NMDAR antibodies
in a subgroup of patients with dementia, the association
with immunotherapy-responsive clinical entities, and the
profound in vitro effects of patient IgA/IgM on hippo-
campal neurons6,23 led to the question how frequent these
antibodies are in different forms of dementia. For this,
archived serum and CSF samples from different dementia
cohorts in Germany and the United States were retrospec-
tively analyzed. Although present in 16.1% of all dementia
patients in the participating tertiary referral centers,
NMDAR IgA/IgM antibodies were disproportionately dis-
tributed with highest frequency of 60% in “unclassified”
dementia not fulfilling routine criteria for the established
dementia forms. These patients frequently showed CSF
abnormalities, a fluctuating disease course and psychiatric
symptoms. NMDAR antibodies were also frequently
detected in FTD, PPA, LBD, and PSP/CBS. Antibodies
were detected much less often in patients with a family
history of dementia or in patients with nondementing
neurodegenerative disorders such as PD. With some
exceptions, antibodies were primarily present in serum,
but not CSF, supporting a peripheral origin of the
autoimmune response.
The frequency of NMDAR antibodies was much lower
in healthy controls and in patients with other neurologi-
cal disorders. Mean ages of healthy controls, AD, PD, and
PPA patients were 66.7, 70.4, 65.2, and 63.5 years, respec-
tively, thus excluding that the low antibody frequency
results from a younger cohort.24 Frequencies of NMDAR
antibody-positive cases vary in the literature. They range
from the absence of IgG-positive cases in >8000 controls
with various disorders25 to the absence in more than 500
healthy control subjects,23,26–29 to the presence of IgG and
further isotypes in 7% of controls, none of them solely
tested against the NR1 subunit of the NMDAR.30 Another
study found NMDAR IgM (but not IgA and IgG) in two
of 21 healthy controls.31 A large recent study used blood
donors as controls and found a ~10% seroprevalence of
NMDAR antibodies, mostly IgM and IgA subtypes.32 One
explanation might be the naturally limited information
about the psychiatric and cognitive status of compensated
blood donors, while the control subjects in the present
cohort were thoroughly investigated for comorbidities
and memory performance.
It remains unclear whether the presence of NMDAR
antibodies in neurodegenerative and dementia patients
simply reflects a biomarker for progressive brain disease
or whether NMDAR antibodies directly participate in the
disease process. It is possible that neuronal degeneration
results in the presentation of neo-autoantigens to the
immune system, in some cases mounting an immune
response with synaptic antibodies that could potentially
lead to synaptic dysfunction and accelerate cognitive
decline. This hypothesis is supported by the documented
effects of patient material on primary hippocampal neu-
rons6,24 and the clinical and radiological improvement in
selected patients receiving immunotherapy. Serum anti-
bodies might find facilitated conditions to penetrate into
the brain in demented patients as the blood–brain barrier
is not preserved at older ages or inflammation.33 In this
way, serum immunoglobulins have been shown to cause
severe neuronal dysfunction in experimental models.34
Also, the clinical differences between NMDAR antibody-
positive and -negative patients (such as more frequent
disease fluctuations, aphasia, and blood–brain barrier dys-
function) support a contribution of NMDAR antibodies
to the clinical phenotype.
It is important to note that IgM/IgA-NMDAR
antibodies do not define anti-NMDAR encephalitis, a
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well-known severe immunotherapy-responsive encephali-
tis.13,27,35 Although patients with anti-NMDAR encephali-
tis additionally had IgA-NMDAR antibodies in 31%,6 the
disease associates with IgG antibodies to a distinct NR1a
amino terminal epitope; furthermore, amino acid N368
within this domain is crucial for epitope recognition.12
Impaired binding of IgM/IgA-NMDAR antibody-positive
serum to rat brain sections (using routine procedures for
IgG detection) further suggests that disease mechanisms,
antibody affinity, and epitopes are different between IgG-
positive anti-NMDAR encephalitis and IgM/IgA-associ-
ated cognitive decline. Indeed, our epitope mapping pilot
studies with two IgA-positive patient sera already demon-
strate that epitopic determinants vary between patients
with anti-NMDAR IgA-associated cognitive decline. Dele-
tion of the ATD reduces antibody binding, but does not
eliminate it, and the presence of this domain is not suffi-
cient to fully preserve binding in both patients. Addition-
ally, N368 is not absolutely required. Given that deletion
of the ATD does not completely eliminate binding, addi-
tional parts of the receptor must also be targeted by IgA
antibodies. The relationship between response to immu-
notherapy, NMDAR epitope, and functional assays of
receptor downregulation should be explored in further
detail; specific epitopes may be associated with distinct
disease pathophysiology, neurologic symptoms, or treat-
ment response.
Based on the present (principally retrospective) study,
it is too early to give definite treatment recommendations
in cases where NMDAR IgA/IgM antibodies are present.
The imaging and in vitro data as well as analyses of the
few cases that received immunotherapy suggest that the
presence of NMDAR-IgA could possibly predict partial
reversibility of the disease with immunotherapy. As the
antibody levels likely play a role in pathogenicity, in
the Charite hospital center, we consider immunother-
apy if repeated NMDAR IgA/IgM antibody titers are
≥1:1000. Preliminary data showing clinical stabilization or
improvement are encouraging, even more so as patients
always presented late in the disease when irreversible neu-
rodegeneration has already occurred. It remains unclear
whether treatment with steroids is sufficient to define
immunotherapy-(non)responsive dementia or whether
further therapy (including plasma exchange, IVIg, ritux-
imab, cyclophosphamide) and longer treatment duration
are required in patients with high-level NMDAR antibod-
ies. One should keep in mind that in a related case of a
patient with VGKC complex (likely LGI1) antibody-asso-
ciated dementia mimicking FTD, the patient improved
from steroids only after a few weeks with further
improvement occurring after several months of therapy.4
The current findings suggest that (1) IgA/IgM NMDAR
serum antibodies are associated with dementia and could
help to identify patients with cognitive decline who might
benefit from immunotherapy, (2) patients with subacute
or fluctuating dementia, CSF abnormalities, further auto-
immune diseases, or atypical forms of dementia should
be tested for IgA/IgM NMDAR antibodies, (3) as most
patients in this constellation have no other treatment
options, repeated IgA-NMDAR antibody titers ≥1:1000 in
our opinion justify an immunotherapy attempt if the cog-
nitive impairment is not explained otherwise, in particu-
lar if little irreversible brain damage has occurred and the
patient is in good physical shape. Future studies should
determine whether the high frequency of NMDAR
antibodies in some dementia groups (such as PPA) is
related to the specific pathogenesis or whether the anti-
bodies define subgroups of the disorder (such as Progres-
sive Nonfluent Aphasia [PNFA]). In addition, prospective
analyses should determine which patients respond to
immunotherapy, whether antibodies against additional
targets (e.g., other synaptic proteins) are involved, and
how antibody levels, epitope binding, and in vitro recep-
tor downregulation using patient serum help to predict
the clinical response.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Frequency distribution, isotypes, and titers of
CSF NMDAR antibodies in study subjects. Number of
subjects per group, percentage of dementia patients and
controls with positive NMDAR antibodies (IgM, IgA, or
IgG) in CSF (top). Antibody isotypes and CSF titers
across dementia groups and controls (bottom).
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